Johnson & Johnson Surprises With Strong Quarterly Results! Pharma Giant Withstands Stelara Loss and Tariff Threats!
Reading Time: 3 minutes
Johnson & Johnson (i)(JNJ) is one of the leading healthcare companies worldwide – with a strong portfolio in pharmaceuticals and medical technology. Despite the loss of significant patent revenues, the company surprised in the second quarter of 2025 with better-than-expected results in revenue and profit. New products and strong MedTech growth instill confidence – leading to a substantial increase in the annual forecast. The share price jumps by over 6% and is nearing $165. Johnson & Johnson - a healthcare giant with a global portfolio...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
